explore -WSS

explore

author：knowledge 2025-10-01 12:11:58 - browse：45641

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： WATCH: Why do fingernails fall off when they're damaged?

hotspot

WSS

Food makers to regulators: Ultra

FDA approves updated Covid vaccines

CDC concerned about possible undetected monkeypox spread in U.K.

Food makers tried to stack nutrition panel with preferred experts

Popular nasal decongestant doesn't actually relieve congestion

White House touts steps to stem shortages of cancer treatments

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Apple is now the first public company to be valued at $3 trillion

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

At least 13 dead in Texas as scorching temps continue

Colonoscopy at 40? Study finds a possible benefit

Guidelines to prevent youth baseball injuries need more muscle

Cloning humans is technically possible. It's curious no one has tried

23andMe had bad news about my health. I wish a person had delivered it

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Wikipedia

Diverse clinical trials: Why aren’t we there yet?

Donald Trump's relentless attacks on special counsel Jack Smith

Disclosing genetic information: not as worrisome as once feared

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

explore

explore

hotspot

explore